Is Compounded Tirzepatide Still Legal? What the FDA Actually Says

Search "compounded tirzepatide" and you will find dozens of telehealth companies still selling it, and dozens of blog posts confidently declaring it legal, illegal, or "in a gray area." Almost none of them cite anything more specific than "the FDA." The FDA, as it happens, has been extremely specific — it has kept a single running timeline on its own site since 2024, updated as recently as April 2026, and most of what gets written about this question ignores it entirely.

Here is what that timeline actually says, with dates.

The shortage that made compounding possible

Compounding pharmacies are allowed to make a copy of a patented, FDA-approved drug under narrow legal exemptions — sections 503A and 503B of the Food, Drug and Cosmetic Act — and one of the biggest exemptions is a drug shortage. When a brand-name drug is officially listed as in shortage, both 503A pharmacies (compounding for a named, individual patient) and 503B outsourcing facilities (compounding in batches) get room to fill the gap without being treated as making an illegal copy of a commercial product¹.

Tirzepatide — sold under the brand names Mounjaro and Zepbound — had been on that shortage list since 2022, driven by demand that outstripped Eli Lilly's manufacturing capacity. That shortage is the entire reason a compounded-tirzepatide industry exists.

The FDA has now said, twice, that the shortage is over

• •October 2, 2024 — FDA determined the tirzepatide injection shortage was resolved, based on the manufacturer's confirmed ability to meet national demand¹.
• •October 22, 2024 — that determination was legally remanded back to the FDA for reevaluation, as part of ongoing litigation (Outsourcing Facilities Association v. FDA).
• •December 19, 2024 — FDA re-evaluated and reached the same conclusion: the shortage is resolved. To soften the landing, the agency gave 503A pharmacies until February 18, 2025, and 503B outsourcing facilities until March 19, 2025, before it would start treating shortage-based compounding as a violation¹.
• •March 5, 2025 — a federal district court denied a preliminary injunction in that same litigation. Per FDA's own update, that meant 503A enforcement discretion "has ended" immediately for state-licensed pharmacies and physicians; the 503B grace window ran through March 19, 2025¹.

Semaglutide (Ozempic/Wegovy) went through the identical sequence on a roughly two-month delay: shortage declared resolved February 21, 2025, 503A discretion ending April 22, 2025, and 503B discretion ending May 22, 2025 after the same court denied a follow-up injunction motion on April 24, 2025¹.

What "the shortage is over" actually closes off

This is the part most secondary coverage skips. A 503A pharmacy is barred from compounding a drug that is "essentially a copy" of a commercially available product — and once the FDA calls a shortage resolved, tirzepatide counts as commercially available again. FDA's own compounding guidance treats a compounded drug as "essentially a copy" when it has the same active ingredient, in a similar or substitutable strength, given the same way, as the approved product — unless a prescriber documents that a specific change (a different dose the manufacturer doesn't make, for example) is clinically necessary for that individual patient¹.

503B outsourcing facilities face a separate, narrower gate: they can only compound from a bulk drug substance if that substance is either on FDA's "503B bulks list," or the finished drug is on the shortage list at the time of compounding. As of FDA's most recent update, tirzepatide and semaglutide are on neither list¹ — which means the shortage-based path is closed for 503B facilities too, not just 503A pharmacies.

FDA does carve out one narrow allowance on the 503A side: it says it does not currently intend to act against a pharmacy that fills four or fewer prescriptions of an essentially-a-copy compounded drug in a calendar month¹. That is a small-scale, patient-specific safety valve — not a basis for a nationwide telehealth subscription business.

So what does that leave, legally, in 2026?

Reading the FDA's own conditions rather than a summary of them, compounded tirzepatide remains on solid legal footing in a few specific situations:

• •A prescriber documents an individualized reason a specific patient needs a dose or formulation the commercial product doesn't offer (the FDA-approved product comes in fixed 2.5-15mg pens; a documented, patient-specific dose outside that range is the clearest example).
• •A patient has a verified allergy or intolerance to an inactive ingredient in the commercial product.
• •A pharmacy stays under the ≤4-prescriptions-per-month threshold for compounding that would otherwise count as "essentially a copy."

What it does not cover, per the agency's own stated position, is bulk 503A or 503B compounding of tirzepatide simply because it is cheaper than the branded product, marketed at telehealth-subscription scale, with no individualized medical justification tied to a named patient.

Why this matters when you're comparing providers

None of this makes every compounding pharmacy dispensing tirzepatide "illegal" — a provider genuinely operating inside one of the exceptions above is on solid ground, and plenty of legitimate 503A pharmacies do exactly that. What it means is that "compounded" and "cheap" are no longer, by themselves, evidence that a provider found a clever workaround — the workaround the whole industry ran on for two years has been legally narrowed since December 2024, in writing, by the agency that enforces it. A provider whose intake never asks why a compounded dose is medically necessary for you, specifically, is not obviously operating inside the exception FDA actually left open.

That is a pharmacy-sourcing question, not a medical one, and it is exactly why our tirzepatide provider comparison reads pharmacy disclosures directly off each provider's own site rather than assuming "compounded" means the same thing at every company.

It is also worth being explicit about a question this article deliberately leaves aside: none of the above is about whether insurance pays for any of this. It generally doesn't, and not as a matter of insurer preference — our look at how GLP-1 insurance coverage actually works walks through why a compounded product structurally sits outside how a pharmacy claim gets billed in the first place, shortage-exemption status aside.

None of this legal-status question is specific to sex, but one consequence of starting tirzepatide is: its FDA label carries an actual warning that it can reduce how well oral birth control works, with a specific recommended fix, and separately, women with PCOS have shown a real (if still early) fertility-restoring effect in trial data — meaning a compounded-intake form that never asks about contraceptive method is skipping a question with real stakes. Our full look at what the label says, and what the PCOS evidence actually shows covers both in detail.

How the providers we've reviewed handle it

None of this determination is specific to any one company — every telehealth provider selling compounded tirzepatide operates under the same narrowed rules above. What differs is how openly each one discloses the pharmacy and compounding details that let a reader judge that for themselves:

• •Precision Telemed's write-up covers the only provider on our board that names both a specific pharmacy and a 503A category on its own product pages.
• •Found's review covers a provider stating a 503A category in its own words — though unlike Precision Telemed, it names no specific pharmacy vendor.
• •Empower Pharmacy's review is a different kind of entry entirely: it is the compounding pharmacy itself, not a telehealth reseller, and states its own 503A/503B status more directly than anyone else here — but it fills prescriptions written elsewhere and publishes no price to the public.
• •The PlexusDx review covers one of twenty providers among the twenty-nine on our board, alongside Fridays, EOS Health, Liberty, Rejuve Meds, Rivo Health, Transparent Meds, StackMD, Trinity Meds, Lttl, Voxy, Eden, Willow, Strut Health, NexLife, BluefitMD, Ivim Health, Viv Health, Kin Meds, and 24HrDoc, that state plainly, in their own words, that their compounded medications are not FDA-approved.
• •CoreAge Rx, reviewed here, advertises a low starting price on our board but names no pharmacy and states no facility category.
• •yourEra's page covers a provider running tirzepatide and several other compounds off one page with no pharmacy named either.
• •Henry Meds' review covers a provider whose own pages disagree with each other on which federal pharmacy category applies — its product page hedges between 503A and 503B while its Terms of Service state 503A alone.
• •Fridays' review covers a provider whose own Help Center states a 503A category and whose Terms & Conditions name four separate partner pharmacies — tied with EOS Health for the most of any reseller here — though not on its product pages the way Precision Telemed names Rush Pharmacy.
• •EOS Health's review covers a provider naming both a clinical partner (Arora Health & Aesthetics, LLC) and five separate 503A pharmacies on its own Clinical & Pharmacy Partners page — but one whose own Terms & Conditions and HIPAA Privacy Policy pages contradict each other about whether HIPAA applies to it at all, even as the site markets "HIPAA-Compliant Care" throughout. Those same five pharmacies also fill EOS Health's Glutathione Injection and Nasal Spray lines, priced separately from $95.20/mo — see our Glutathione provider comparison for how that disclosure holds up compound-to-compound, not just for tirzepatide.
• •Welling Health's review covers a provider whose own FAQ states a 503A category directly — but whose homepage GLP-1 Therapy card contradicts that in the same card, calling the same pharmacy "503A" in one line and "LegitScript-certified 503B" in the next, and which names no specific pharmacy anywhere on the site.
• •Liberty's review covers the first provider on our board stating a 503B category — FDA-registered outsourcing facilities, stricter than the 503A pharmacies most others here use — but whose own comparison table advertises a tirzepatide price ($299/month) that its own product page doesn't actually charge ($219/month), and whose site can't agree with itself on whether it's licensed in 47 or 50 states.
• •Rejuve Meds' review covers a provider naming an actual fulfillment network ("Rejuve Meds Pharmacy Network") and clinical partner (Beluga Health, P.A.) in its own Terms — but no specific pharmacy or 503A/503B category anywhere on the site, and a "$265/month" tirzepatide figure advertised sitewide that its own live billing data shows is a 12-month, $3,180 prepay plan amortized down, not a monthly charge; its actual no-commitment rate is $349/month, and its own checkout is configured to hide the total and default toward the prepay tier.
• •Rivo Health's review covers a provider naming no pharmacy and no 503A/503B category anywhere on the site — and whose own checkout billing data shows its featured "$199/month" tirzepatide price is a one-cycle introductory rate that auto-renews near double, at $349/month, starting the second charge, disclosed nowhere on the marketing site itself.
• •Transparent Meds' review covers a provider whose brand name is the claim under test: it names both a clinical network (Locum Tele) and a compounding pharmacy (Rush Pharmacy — the same pharmacy Precision Telemed names and classifies 503A above) but states no regulatory category for either, and its own compiled source code labels its featured "$99/$199 Monthly price" introMonthly next to an unexplained "List price" of $229/$349 that is never disclosed as such anywhere a reader sees it.
• •StackMD's review covers a provider with genuinely real, verifiable dose-tier pricing ($199 to $449 as tirzepatide strength climbs from 5mg to 30mg, confirmed directly against its own live product data) — but no pharmacy is named anywhere on the site, and its own Platform Disclosure page hedges dispensing between "503A pharmacies, or 503B outsourcing facilities" the same way Henry Meds' pages disagree with each other, without ever resolving to one. Its Terms of Use instead name a separate telehealth partner, SamaritanMD, as the party solely responsible for clinical care, billing, and refunds — a real, disclosed split, though StackMD's own /sermorelin/ marketing page separately advertises a price that its own shop and homepage don't actually charge (see our sermorelin comparison for that finding).
• •Trinity Meds' review covers a provider naming four partner pharmacies directly (more specific than most peers here) but tying none of them to a 503A or 503B category anywhere on its site. Its own pages also can't agree on who provides the actual clinical care — "CareValidate Health" per its Terms & Conditions, "OpenLoop Health" per its own FAQ and Refund & Cancellation Policy — or on its own tirzepatide price: a "Military Discount Pricing" banner reads $149/month on five live pages and $199/month on a sixth, its own Refund & Cancellation Policy.
• •NuBloom's review covers a provider with an unusually clean, flat $279/month tirzepatide price and no pharmacy named at all. Its disclosure is genuinely contradictory rather than simply absent: a compliant disclaimer stating compounded drugs "are not FDA-approved" exists on its homepage and category pages, but its own FAQ separately and unhedged tells a reader "NuBloom prescribes FDA-approved weight loss medications, including peptides such as GLP-1s" — and nothing on that FAQ page corrects it. Its live Terms of Service compounds the theme: the Governing Law clause names no actual state, just the literal unfilled placeholder "the State of [STATE]."
• •Lttl's review covers a provider naming four partner pharmacies directly in its own Terms of Service — RedRock Pharmacy, Health Warehouse, Precision Compounding Pharmacy, and Triad Rx — tying none of them to a 503A or 503B category anywhere on its site. Its own FAQ states plainly, and accurately, that its compounded GLP-1s "are not FDA-approved." The deeper issue is its own headline price: a section literally titled "Compounded GLP-1, Priced Honestly" advertises tirzepatide "As low as $199/mo," which its own pricing table states, in the same breath, is the 12-month prepay rate — the real no-commitment monthly price is $279.
• •Voxy's review covers a provider stating a direct, unhedged 503A claim on its own product pages ("Compounded medications are prepared by a licensed 503A pharmacy") and naming both a specific pharmacy (VialsRX, Houston TX) and a clinical/prescribing partner (Arora Health & Aesthetics, LLC, Seattle WA) on a dedicated Compliance page — the same clinical partner EOS Health, above, also uses. Its own hero price ("Starting at $199/mo") is, again, the 12-month prepay tier; the real no-commitment monthly price is $299. The more unusual finding: no terms-of-service, cancellation, or refund policy exists anywhere on the live site, under any path — only a Privacy Policy and the Compliance page, neither of which addresses cancellation or refunds at all.
• •Kova's review covers a provider whose marketing site never names a specific compound anywhere — homepage, FAQ, and every legal document all stay at "GLP-1 medication" — a real gap this site's own provenance rule would normally disqualify outright. It clears the bar anyway: the compiled JS behind its checkout app (a separate /survey/app flow) names both compounds directly in real paywall copy ("May contain compounded semaglutide, if prescribed" / "Compounded tirzepatide"), tied to two distinct product tiers. Its own FAQ separately contradicts itself on which pharmacy fills the prescription — one answer names a single hedged network ("Telegra Pharmacy Network," itself hedging between 503A and 503B), a different answer on the same page names four entirely unrelated pharmacies instead.
• •Eden's review covers a provider that names and links its own compounding pharmacy, edenpharmacy.com — a real, independently-indexed acquisition (Contigo Compounding, August 2025) rather than an unnamed network — but the 503A category behind that pharmacy is stated only in a linked press release, never on eden.health's own pages. Its flat $199/mo tirzepatide price is real, but a required Eden Membership stacked underneath it (disclosed only in a footnote, never next to the price itself) pushes the true standing cost to $298/mo.
• •Willow's review covers a provider naming three partner pharmacies directly, with full addresses, in its own Terms — but no 503A/503B category for any of them. Its flat $399/mo tirzepatide price is genuinely real, with no membership fee or other charge found stacked underneath it anywhere on the site, a cleaner story than several peers here. The gap instead sits in its own FAQ, which tells a needle-averse reader that oral dosing is "Semaglutide only" — contradicted by its own /tirzepatide-tablets product, sold at the identical price, one click away in that same FAQ page's own footer nav.
• •Strut Health's review is the one entry on this list where the "still legal, under narrower rules" question above stops being abstract: FDA itself issued the company a warning letter (MARCS-CMS 721448, dated February 20, 2026) after reviewing its site in December 2025 and finding compounded-tirzepatide product labels that identified "Strut" as the compounder (it is not) and marketing claims — "Generic Zepbound, Mounjaro," "Tirzepatide is the active ingredient in the brand medications Zepbound® and Mounjaro®" — that FDA says falsely implied FDA approval, misbranding under FDCA §502(a)/§502(bb). A live check of the current site, roughly five and a half months later, found neither the quoted phrase nor a "Strut"-branded label anywhere on the pages and product images checked, suggesting at least partial remediation. Separately, its own product pages headline an auto-refill price ($199/mo "As low as") while a distinctly-priced one-time SKU a few lines down the same page states the real 30-day price is $325 (injectable) or $239 (oral).
• •NexLife's review covers a provider whose own FAQ publishes a genuinely undisguised price table ($215/mo standing, with clearly-labeled optional prepay tiers below it) and a real, checkable LegitScript seal — but whose FAQ self-contradicts on regulatory category (unhedged 503A in two answers, an admitted 503A/503B mix in a third) and whose marketed "lose up to 10% in 6 months or your money back" guarantee turns out, on its own dedicated policy page, to require having lost LESS than 5%, six unbroken months of wearable-verified adherence, and a claim filed in a single 30-day window — with the medication cost itself excluded from any refund it does pay.
• •MEDVi's review covers a provider FDA also issued a warning letter (MARCS-CMS 721455, February 20, 2026) over compounded-drug labeling — the same mislabeled-compounder template as several other providers on this list — and whose own tirzepatide landing page states two different prices for the same drug on the same page.
• •BluefitMD's review covers the second provider on this board with its own dated FDA warning letter from the identical February 20, 2026 wave (MARCS-CMS 721446) — read directly, its specific violations differ from Strut Health's: labels identifying "BluefitMD" as the compounder (false), plus "same active ingredient as Ozempic®/Wegovy®" and "Mounjaro®/Zepbound®" claims FDA says imply approval. States a direct, unhedged 503A category on its own About and Safety Info pages, but its own Policies page claims pricing "remains consistent regardless of dosage adjustments" — contradicted by checkout data showing its true tirzepatide price more than doubles by dose ($325 to $775/month, against a $225/mo prepay headline) — and its own footer LegitScript badge fails to resolve at LegitScript's own CDN.
• •Ivim Health's review covers the third provider on this board with its own dated FDA warning letter from the identical February 20, 2026 wave (MARCS-CMS 721816) — read directly, it's the same single-issue template as the first of BluefitMD's two citations, and nothing else: labels identifying "Ivim" as the compounder (false). States no 503A/503B category anywhere, only a vague "FDA-inspected, state-regulated compounding pharmacies" claim. Its own $133/mo tirzepatide headline omits a mandatory $74.99/mo membership disclosed only in small print on the same page — and, independently, its own live qualification-quiz configuration discloses a materially different $249/month price, payable upfront, for the same product category. A real, checkable identity (BBB-accredited since 2023, A+ rating) with a LegitScript seal that actually resolves, unlike BluefitMD's — but its own Terms and Membership Agreement can't agree on whether Michigan or Ohio law and venue actually govern the company.
• •Viv Health's review covers the fourth provider on this board with its own dated FDA warning letter from the identical February 20, 2026 wave (MARCS-CMS 721818) — the same single-issue template as Ivim Health's: labels identifying "VIV RX" as the compounder (false). States no 503A/503B category anywhere, despite naming four fulfillment pharmacies directly by name and address. The more unusual finding is independent of the FDA letter entirely: its own shared FAQ block, rendered across its homepage and every product page, answers a pricing question by naming a different company — "Eden offers a comprehensive package that includes ongoing support and regular check-ins" — not VIV RX, and its own Privacy Policy commits a visitor to a Terms of Service and Telehealth Authorization and Consent that don't exist anywhere on the live site.
• •Kin Meds' review covers the fifth provider on this board with its own dated FDA warning letter from the identical February 20, 2026 wave (MARCS-CMS 721450) — read directly at fda.gov: the same mislabeled-compounder template ("Kin Meds" pictured on labels, false), plus two marketing claims cited by name — "Same Active Ingredient as common brands" and a "same weight loss ingredient as brand-name GLP-1 medications" line — that FDA says separately implied approval, the same two-claim shape as BluefitMD's letter. States no 503A/503B category anywhere, despite naming a specific fulfillment pharmacy (Rush Pharmacy) directly in its own FAQ — but its own Returns and Refund Policy separately gives a different pharmacy's address (Strive Pharmacy) as the return destination for the same prescription products, an unresolved first-party contradiction about who actually fills the order. Its own LegitScript seal (ID 29592772) does resolve (HTTP 200), and the FDA letter's own addressee address matches the address in Kin Meds' own site-wide structured data exactly.
• •24HrDoc's review covers the sixth provider on this board with its own dated FDA warning letter from the identical February 20, 2026 wave (MARCS-CMS 717984) — read directly at fda.gov: the same mislabeled-compounder template ("24HrDoc" pictured on labels, false), plus two marketing claims cited by name — "Same ingredients as: Ozempic and Wegovy" and "Same ingredients as: Mounjaro and Zepbound" — that FDA says separately implied approval, the same two-claim shape as BluefitMD's and Kin Meds' letters. States no pharmacy or regulatory category anywhere — fulfillment is described only as "licensed compounding pharmacies" and "trusted partners." The more unusual finding is independent of the FDA letter entirely: its own dedicated, injectable-Tirzepatide product page carries benefits copy that names the wrong drug ("Clinically studied active ingredient – semaglutide") and closes by asking if a reader is ready to lose weight "without the needle" on a page selling a weekly injection, and its own live Terms & Conditions page still contains unfilled legal-template placeholders in production, including two literal "[INSERT EMAIL]" strings.
• •Bodybuilding Health+'s review covers a real, LegitScript-verified telehealth brand under the Bodybuilding.com umbrella. Its tirzepatide price follows a disclosed teaser pattern — "$209 first month" beside a printed "regular price" of "$319" — at least findable on the same page, unlike peers that omit the standing rate entirely. No pharmacy is named anywhere on the site, and no state list is published.
• •HealthSource's review covers a provider backing an unhedged "all 50 states" claim and stating a 503A category for its unnamed "partner pharmacy" on every product page. The real gap: every price is quoted "every 4 weeks," not monthly — a real distinction (13 charges a year, not 12) its own Terms of Use never disclose, describing billing only in generic monthly-sounding language.
• •PepHaūs' review covers the only provider in this batch to name a specific pharmacy AND state a 503A category on the same page — two pharmacies, Greenwich Rx and Hallandale Pharmacy, both cited directly on its own /how-it-works page. Its pricing is unusually clean (a real "Pay as you go" no-commitment rate on every product), but no state list is published anywhere on the site — the only statement is "shipping availability for your state is confirmed at checkout."
• •Rylo Health's review covers a provider naming an actual fulfillment pharmacy with a full address and phone number (VialsRX, Houston, TX) and backing an unhedged "all 50 states" claim — but its lowest advertised tirzepatide price is fronted by a live "First 20... 17 of 20 spots left" scarcity counter, and its LegitScript badge is served from its own domain rather than resolving against LegitScript's own CDN.
• •Vytora Health's review covers a provider with the cleanest standing-price disclosure of this batch — "$249/month... Billed monthly. Includes everything," no first-month teaser to decode. Its own /about page names two fulfillment pharmacies directly, but neither is tied to a 503A/503B category, and both turn out to be the same shared vendors Rylo Health and PepHaūs each name for themselves elsewhere on this board.
• •Yucca Health's review covers a provider that states its true no-commitment month-to-month tirzepatide price directly beside its discounted 6-month prepay rate on the same page — an honest disclosure most peers on this board don't bother making. The gap: its own Terms of Service disclose that subscription renewals are "processed 5-7 days early," and no pharmacy is named anywhere on the site.
• •PreventiveMD's review covers a provider whose own pricing page is the most literally transparent on this board — every plan tier (1/3/6/12-month) shown together in one table, nothing gated behind a click. The catch: PreventiveMD's own sitewide headline still quotes only the cheapest, 12-month-prepay figure ("as low as $97/mo") while the real 1-month price shown two inches below it on the same page is $139/mo, 43% higher.
• •TelePeptide's review covers a provider that states its true no-commitment monthly tirzepatide price ($249/mo) directly beside its 3/6/12-month prepay tiers on the same /pricing page — a genuinely honest disclosure. The gap: no pharmacy is named anywhere on the site, and neither "503A" nor "503B" appears, the least specific pharmacy disclosure of this batch.
• •Vyora Wellness's review covers a provider with a flat, unhedged $399/month tirzepatide price and no prepay tier to decode. The gap turns up in its own Refund Policy, not its pricing page: "our standard shipping interval for monthly subscription products is every three (3) weeks" — a "monthly" subscription that actually bills roughly 17 times a year.
• •REMEVi's review covers a provider whose homepage names four fulfillment pharmacies directly with a checkable LegitScript seal (ID 50384507, confirmed live) — but whose own tirzepatide-page FAQ states its semaglutide is compounded by a "503B outsourcing facility," directly contradicting the homepage's unhedged 503A claim for every named pharmacy.
• •RxPepsDirect's review covers a provider that sells no subscription at all — a dose-scaling vial price (tirzepatide climbing from a $45, 12mg Month-1 vial to $247.50 by Month 6) plus a $39 telehealth fee charged on every reorder, per its own FAQ. It names its fulfillment pharmacy (Optimal Balance Pharmacy, Texas, 503A) directly on the same page as the price — but its own Refund Policy states plainly it "does not sell, dispense, ship, or collect payment for medications," directing any medication billing dispute to that pharmacy instead.
• •YourHealthRx's review covers a provider whose own tirzepatide product page honestly discloses a first-month promo distinct from the standing rate ("$190 first month then $210/mo billed monthly, cancel anytime") — but whose homepage headline still quotes the $190 first-month figure as if it were the going rate.
• •Trimi's review covers a provider that names two specific 503A pharmacies directly on its own FAQ page — VialsRx and GreenwichRx — clearing this board's pharmacy bar more cleanly than most peers here. The gap: its own homepage and FAQ headline a 12-month prepay rate ($125/mo) in most placements, while its own product page discloses the real no-commitment rate is $235/mo, 88% higher.
• •Oak's review covers a provider with an explicit, first-party "One price · All dosages · No subscriptions" claim next to its headline price — a real, checkable no-commitment claim this board rarely sees stated this directly. The gap: no pharmacy is named anywhere on the site, and no 503A/503B category is stated for any product.
• •Direct Meds' review covers a provider whose own product pages state a real, flat, no-subscription price for all three of this site's boarded compounds — the cleanest pricing disclosure of the newest additions here. FDA issued the company a warning letter (MARCS-CMS #716822, September 9, 2025) — the earliest-dated letter on this list, and no close-out letter had been issued as of this review — over marketing language equating compounded tirzepatide to the FDA-approved brand.
• •Alternate Health Club's review covers a provider with a genuinely flat, dose-independent tirzepatide price ($169/mo, confirmed against its own shop) and a real 503A category claim — undercut by its own Terms & Conditions, which name New York as the governing law in one section and Wyoming in another, for two parts of the same document.
• •AquaVita NextGen's review covers the online storefront of a real, physical medspa (independently confirmed via its own Google Maps and Yelp listings) with clean, disclosed per-unit tirzepatide pricing ($320 one month, $900 three months) and a specific 5-state list — but no Terms of Service, Privacy Policy, or Refund Policy exists anywhere on the live site.
• •Belle Health's review covers a provider naming four pharmacy partners directly and a clean, unhedged all-50-states claim — but its own homepage and its own /treatments pricing page disagree on the tirzepatide price by $24/month, with no promo framing on either side to explain the gap.
• •Care Bare Rx's review covers a provider that names both oral and injectable tirzepatide directly on its own product page — the clearest compound-naming disclosure of a shared-backend group of sibling sites this round of research covered — and states a 503A category for its 4-pharmacy network on its own /faq page. The gap: two of its four named pharmacy partners (Belmar Pharma Solutions, Strive Pharmacy) carry real FDA warning letters, and its "From $199/mo" headline is a disclosed floor, not a fixed price.
• •Breeze Meds' review covers the same shared-backend group's third storefront — an earlier automated research pass wrongly reported it never names a specific compound, but its own navigation menu names "Tirzepatide Injection" directly. The real gap: pricing is quiz-gated to a category-wide "Starting at $199," and none of its four named pharmacy partners (the same four Care Bare Rx names) is tied to a 503A/503B category anywhere on the site.
• •Gala Health's review covers a provider verified live by completing its own checkout funnel through the real plan-selection screen — a step a plain fetch cannot render. Its tirzepatide checkout shows a genuine $399/month Monthly (no-commitment) sticker price, but headlines a "$179 LIMITED OFFER" first-shipment price gated behind a fake-scarcity "Only 24 discounts left" counter and a countdown timer — the exact same $179 figure it also shows for semaglutide, despite that drug's real $299/month rate, meaning the number isn't tied to either drug's actual cost at all.
• •Big Easy Weight Loss's review covers a provider whose own /pharmacy-partners page individually names six pharmacies, each with its own stated 503(a)/503(b) category and its own state-exclusion list — the single most granular per-pharmacy disclosure independently found in this whole research round. The gap: its own dedicated tirzepatide product page never states a monthly price, only "Starting at $599 / 12 week plan," with a same-page new-patient discount toggle down to $499 and "installment pricing" offered only as financing that spreads that same package total, never a lower recurring rate.
• •Cora Health's review covers a provider that names two specific 503A pharmacies by name (Hallandale Pharmacy, VialsRx) and discloses all four of its own pricing tiers side by side on one /plans page, labeled by billing cadence — genuinely transparent structure. The gap: its own homepage and page metadata still headline the 12-month-prepay figure ("$135/month") in most placements without the "annual" qualifier attached, while the real no-commitment "billed monthly" rate, stated two clicks away, is $225/month, 67% higher.
• •Ondra Health's review covers the only provider in this whole research round whose own pricing page states its prepay mechanism outright, in plain words — "The lowest per-month prices reflect the 6- and 12-month plans, billed in full up front" — yet its homepage hero still headlines that same lowest figure ("From $96/mo," actually its semaglutide tier) rather than the $219/month tirzepatide no-commitment rate its own pricing table discloses two sections down.
• •OrderlyMeds' review covers what the cleanest version of this disclosure looks like: its own /pricing page states its new-patient promo ("$149/mo $299 for 2 months," explicitly labeled a new-customer special) directly beside a separate "Monthly plans... $299" line with no promo language attached, both on the same page. The gap: its own FAQ names its three fulfillment pharmacies and its 503A claim in two separate sentences, never tying a specific pharmacy to that category by name.
• •Tryozi's review covers a provider that names its pharmacies AND their category in a single sentence, the cleanest same-citation match found this round: "Licensed U.S. 503A compounding pharmacies: RedRock, Health Warehouse, Precision Medicine, Triad Rx." The gap: its featured homepage price ("$189") is explicitly a first-4-weeks-only discount shown on the same line as the real standing rate, $379/month, exactly double.
• •DrMedHealth's review covers a provider that repeats "$299/month" for tirzepatide identically across its homepage and FAQ with no "starting at" qualifier — a genuinely flat price. The gap: that same homepage states "Available in All 50 States" in one section and "All 50 US states plus Washington DC" in its own FAQ answer just below it, a live self-contradiction on a single page.
• •PeterMD's review covers a provider that names two pharmacies directly in its own Terms & Conditions and discloses a specific two-state exclusion list. The gap: its "$249 per month" tirzepatide plan is billed quarterly, not monthly — the plan card discloses "billed quarterly" on the same line, so the real charge lands as one ~$747 payment every three months, not a monthly line item.
• •altRx's review covers a provider whose own product card shows "Starting at $299/mo $149/mo" — the featured $149 figure struck through against the real reference rate, and its own coupon-code system independently confirms the lower price is first-month-specific. The one genuine strength: a company-wide, unhedged 503A claim stated directly in its Terms of Service.
• •Jently's review covers a provider that names its pharmacy AND its 503A category in the same sentence — "Precision Compounding Pharmacy..., a state-licensed 503A compounding pharmacy" — and discloses its real "MONTHLY RETAIL PRICE" ($259) on the same page as its 3/6/12-month prepay tiers, a transparent same-page disclosure rather than a hidden commitment trap.
• •FitFlow's review covers a provider whose own /treatments page shows "$134 $109 per month Limited time only" for tirzepatide — a struck-through reference price sitting beside an explicitly time-limited promotion on the same card, the honest reading being that $134 is the real standing rate.
• •GobyMeds' review covers a provider with a clean "Starting at $133/m" tirzepatide price that checks out against its own 3-month bundle math — undercut by a sitewide "Offer ends December 31st, 2025" promo banner still live on its homepage months after that date passed.
• •Mochi Health's review covers a provider whose "$79/month" figure turned out to be a real, standing membership fee — but its own product page states plainly, "Cost of medication not included in Mochi Health Membership Fee," with tirzepatide itself priced separately starting at $199/month on top of it, a true combined floor near $278/month.
• •TrimRx's review covers a real SPA whose "Starting at $259" tirzepatide price is invisible to a plain-text fetch, mined instead from its own compiled site bundle. The gap: an order becomes non-refundable the moment intake is submitted, before the medication ships or a price is even confirmed at checkout.
• •ReadyRx's review covers a provider whose own checkout page silently auto-applies a coupon code to every visitor by default, discounting the first month only — the true standing $315/month tirzepatide rate was confirmed by querying its own live pricing API directly, not by reading the page's marketing copy.
• •RxION Health's review covers a provider that discloses its true 1-month, no-commitment tirzepatide price ($299/mo) directly beside its 3- and 6-month prepay tiers on the same page — genuinely transparent — but whose LegitScript badge links only to a generic keyword-search tool rather than a checkable seal.
• •PepScribe's review covers a provider that names FOUR 503A pharmacies directly on its own /pharmacy-partners page, more specific than most peers on this board — but publishes only an undifferentiated $159-$548 range across every therapy, with no tirzepatide-specific price found anywhere.
• •Direct GLP1's review covers a Direct Primary Care model where a mandatory $89/month membership fee is required on top of the medication price to buy anything at all — its own $133/mo tirzepatide headline never appears beside that fee, so the true floor is $222/mo, not $133.
• •Lemonaid Health's review covers a large, well-known telehealth brand whose own product page states both its $299/month tirzepatide price and its $49/month membership fee together, on the same page — a $348/month combined cash cost disclosed together rather than split or hidden.
• •SkinnyRx's review covers a real Vite/React storefront that serves a complete, content-full page only to certain crawler user agents — a Googlebot UA reveals a real, unhedged 503A pharmacy claim and a $299/mo "As low as" tirzepatide price that a plain fetch cannot see at all.
• •Blue Haven Rx's review covers a provider with an unusually clean claim — "a flat $259/month for tirzepatide... no additional fees" — undercut by its own pharmacy-category claim, "503A Outsourcing Facilities," which mixes two different FDA terms in one unresolved phrase.
• •Momentum Health 360's review covers a provider charging a real, live-confirmed $499/mo for tirzepatide that also received an FDA warning letter (MARCS-CMS 728286, June 8, 2026) for implying it compounds its own medication when it does not — the identical single-issue template already documented for several peers on this board.
• •Join Josie's review covers a provider whose own FAQ admits the price shown on every product card reflects its 12-month prepay plan, not the true $349/mo month-to-month rate — disclosed only in the FAQ, never beside the price itself. It also received an FDA warning letter (MARCS-CMS 717986, February 20, 2026), the same template as 24HrDoc, Ivim, Viv Health, BluefitMD, and Kin Meds above.
• •Embody's review covers a provider whose own tirzepatide product page tags a "SAVE $100" badge on its sale price — but the actual gap between its $349/mo regular price and $129/mo sale price is $220, a mathematically wrong savings badge on the literal purchase page.
• •Bionomy Health's review covers a provider with a flat, unhedged $249/mo tirzepatide price and a genuinely no-lock-in, pay-per-refill billing model. The gap: one of its two named fulfillment pharmacies, Strive Pharmacy, has its own real FDA warning letter (August 2022) and a follow-up Form 483 (September 2023) for sterile-compounding violations.
• •CLYR Health's review covers a provider naming a specific fulfillment pharmacy (The Pharmacy Hub, Miami, FL) directly with an unhedged 503A claim. The gap: its own "$199/mo" refill label doesn't match its own billing mechanics — the actual charge is "$398 billed once" per 8-week cycle — and its own homepage states three different, unreconciled numbers for state coverage in three different sections.
• •He & She MD's review covers a provider naming two fulfillment pharmacies directly and a real, specific single-state exclusion (Louisiana). The gap: its own "$199 to start" tirzepatide headline is a 6-month promotional rate — its own footnote, on the same page, discloses the plan renews at $289/month after that, a 45% jump.
• •Elara Health and Wellness's review covers a provider naming four fulfillment pharmacies directly with an unhedged 503A claim and a clean "all 50 states + DC" claim. The gap: its own "$267/mo" homepage headline is an annual-prepay rate — its own dedicated /tirzepatide page states the true no-commitment price is $339/mo, 27% higher.
• •Luma Meds' review covers a provider selling all three of this site's tracked compounds from one company, with sermorelin explicitly labeled "Compounded" on its own product page. The gap: its own pricing table's raw HTML shows a "3-Month Plan" row labeled "$50 OFF" — but the real gap between the crossed-out price and the discounted price is $383/mo for tirzepatide, not $50.
• •MaxLife's review covers a provider whose own tirzepatide price is flat and honest at $195/mo, with three fulfillment pharmacies named directly. The gap: MaxLife itself received its own FDA warning letter (MARCS-CMS 721453, February 20, 2026) from the same mass-enforcement wave documented above, and one of its three named pharmacies, Strive Pharmacy, carries a separate letter of its own.
• •NewSelf's review covers a provider with a real, specific two-state exclusion (Mississippi, Louisiana) and flat pricing across every dose. The gap: its own homepage headlines an "As Low As $144.49" price with no disclosed mechanism anywhere on the site, its own refund policy charges a fee to cancel even before the doctor visit, and NewSelf itself received an FDA warning letter (MARCS-CMS 721472, February 20, 2026) from the same wave.
• •RxPros' review covers a provider with a real, verified LegitScript seal and flat pricing across every dose. The gap: its own homepage states four different tirzepatide prices across different sections of the same page — the most prominent one, framed as flat and "No Membership," is disclosed elsewhere on the same page as an annual-prepay rate.
• •Zera Health's review covers a provider selling all three of this site's tracked compounds from one company, naming Strive Pharmacy directly as its dispensing pharmacy. The gap: each of its three dedicated product pages' promotional price chip doesn't match either figure in that same page's own pricing table further down, and its own refund policy allows none except for medical disqualification.
• •Peak Wellness' review covers a provider with unusually transparent tirzepatide pricing — the standing $349/mo rate is stated plainly beside the $279 first-month rate, and the 3-month/6-month savings math checks out exactly. The gap: its own Terms & Conditions allow charging a renewal up to three days before the stated billing date.
• •SnagRx's review covers a provider whose own homepage claims "Locked-In Flat Pricing for Life" directly beside a live countdown badge (frozen at zero) claiming the tirzepatide price is about to increase — a self-contradictory claim on the same page, with no page anywhere disclosing what a returning customer is actually charged.
• •RestorLife Med's review covers a provider selling all three of this site's tracked compounds from one company, with a named, board-certified founding physician. The gap: its own homepage FAQ states "available in all 50 states," but its own Terms of Use say coverage is limited to "certain states" only — two of its own pages disagree — and its Membership Fee bills every 28-30 days, not calendar-monthly.
• •Nova MD's review covers a provider selling all three of this site's tracked compounds from one company at a flat, fully disclosed tirzepatide price ($199/mo, no promo-vs-standing gap). The gap: once an order is sent to the pharmacy, its own Refund Policy locks cancellation and refunds for 10 days even if the package hasn't shipped, and a pre-pharmacy cancellation still keeps a $25 consult fee.
• •Maves' review covers a provider selling all three of this site's tracked compounds from one company with a genuinely verified LegitScript seal — its two seal-image URLs both independently resolve at static.legitscript.com. The gap: its own Terms of Service use the identical "approximately every 28-30 days" / non-refundable Membership Fee language already documented for RestorLife Med above, a shared legal-template pattern rather than the same company. One more provider this round sells compounded tirzepatide too, but its own recurring price could never be confirmed: Neo Soma Healthcare names a "Pure Tirzepatide base + Glycine + B12" product at "$330" with no monthly rate disclosed anywhere reached, so it is not ranked on this board — its own Terms of Service separately state the site is "not tailored to comply with" HIPAA, a finding worth reading regardless of which board it's on.
• •HealthRX's review covers a provider with structured, table-disclosed tirzepatide pricing across four plan lengths and a direct, unhedged 503A claim repeated in its own footer. The gap: no page anywhere on the site — Terms, Privacy, HIPAA, About, or its own Returns & Refund Policy — names an LLC, Inc., or Corp. behind the brand.
• •Zappy Health's review covers a provider naming its compounding pharmacy directly ("The Pharmacy Hub, a licensed 503A pharmacy") and selling all three of this site's tracked compounds. The gap: its own homepage headline price is a first-time-only 3-month prepay pack — the real, billed-monthly standing rate, disclosed further down the same page, is $70-100/month higher — and a real FDA warning letter is on record (MARCS-CMS 717991, February 20, 2026).
• •Aurelius Health Group's review covers a provider selling a specifically named microdose tirzepatide protocol ("1mg microdose tirzepatide") at a clean, disclosed standing price. The gap: its own Terms of Use rule out any refund of any fee, in whole or in part, with no exception carved out.
• •Ozari Health's review covers a provider selling all three of this site's tracked compounds from one company, naming two specific 503A pharmacies directly. The gap: one of those two, Hallandale Pharmacy, carries a real FDA warning letter (2020, sterile-compounding deficiencies) — closed out by FDA in 2022 as adequately addressed — and Ozari's own Terms of Service state a blanket 3-month subscription minimum that its "Month-to-Month" pricing tier doesn't disclose.
• •Näky's review covers a provider whose real 1/3/6-month tirzepatide price ladder ($295 down to $265/mo) sits inside a collapsed accordion a plain fetch never reaches — the homepage headline is the deepest, 6-month-prepay tier of that same ladder. Its own Refund Policy rules out any refund of a charged fee, in whole or in part.
• •Citizen Meds' review covers a provider with a rare, cleanly-labeled one-time price — "$145... no subscription necessary" — with a cheaper optional auto-refill disclosed on the same page, no hidden gap. The catch: no legal entity name is disclosed anywhere on the site, and its own Refund Policy is a flat, unhedged "no refund policy."
• •Corsica Health's review covers a provider disclosing both a "1 Month Plan" standing rate ($349/mo) and a labeled "3 Month Plan" discount on the same product page — genuinely transparent. The gap: its own Terms & Conditions rule out any refund of consult fees, and state "all sales are final."
• •Fitish RX's review covers a provider with a genuinely flat "$339... Regular price" for tirzepatide, no promo-vs-standing gap to decode. FDA issued the company a warning letter (MARCS-CMS 728280, June 8, 2026) — the most recent letter on this list — over the same mislabeled-compounder claims documented for several peers above, with no close-out letter found yet.
• •Remi Meds' review covers a provider with a clean, dose-tiered GLP-1/GIP price ladder ($349-$639/mo, rising with dose as expected). The gap: no legal entity name is disclosed anywhere on the site — its own Terms and Conditions name only a third-party arbitration administrator, never Remi Meds' own entity.

Two more providers checked this round sell adjacent products but are not ranked on this board: SkyRx's own review covers a provider that lists tirzepatide in its product catalog, but its own pricing section marks both SKUs "coming soon," directly contradicting its own FAQ's claim that "both of our GLP-1 weight loss medications are real prescription medications" today — only its compounded semaglutide is actually orderable, ranked on the sibling board instead. Nuform Health's own review covers a provider that sells a "GLP+GIP Vitamin Blend" described as compounded, but never names tirzepatide specifically as the active ingredient anywhere on the site, so it is not ranked on this board at all — it is ranked only on the sermorelin board, the one compound its own site names directly.

Strut Health, BluefitMD, Ivim Health, Viv Health, Kin Meds, and 24HrDoc were not the only companies FDA's February 20, 2026 action reached — that was a single-day sweep against 30 telehealth companies, and this site independently researched a seventh one from that same list: MEDVi, a real, live compounded-tirzepatide seller (medvi.org) that received its own warning letter that day (MARCS-CMS 721455, an identical "identifies itself as the compounder when it is not" finding). MEDVi is not reviewed or ranked on this site — independent investigative journalism (Futurism; Drug Discovery and Development) separately documented deepfaked before-and-after patient photos and thousands of ads run under fabricated AI "doctor" personas on MEDVi's own marketing, continuing after the FDA letter, which this site treats as disqualifying rather than a knock a ranked review can simply name and move past. The same check was run against BluefitMD, Ivim Health, Viv Health, Kin Meds, and 24HrDoc before each was added above, and turned up nothing in that class for any of them — for Ivim, the only "lawsuit" coverage a general search surfaces is a template mass-tort marketing page with no docket, court, or named plaintiff, not documented litigation; for Viv Health and Kin Meds, general search surfaced nothing beyond the FDA letter itself and, for Viv Health, unrelated companies sharing a similar name; for 24HrDoc, a real federal lawsuit does exist (Hedrick v. 24HRDOC LLC, S.D. Tex., filed February 2025), but it is a website-wiretapping claim over session-recording technology, the same class of suit filed against large numbers of e-commerce and telehealth sites industry-wide, not a clinical-fraud or fabricated-identity claim, and it predates the FDA letter. Ivim Health is, however, a genuine party to the Outsourcing Facilities Association v. FDA litigation discussed earlier in this article — not as a defendant, but as an amicus: it filed its own 26-page brief supporting OFA's challenge to FDA's compounding restrictions, confirmed directly rather than assumed.

This is a different question from the shortage-and-compounding-law question above, and it is worth reading separately — a company can be fully compliant with FDA's compounding rules and still tell you very little about who actually fills the prescription. Sermorelin and the other growth-hormone secretagogues run under a related but distinct compounding framework (they were never on FDA's GLP-1 shortage list); see what we found ranking that category if that is the category you are researching. Once a prescriber has actually given you a compounded tirzepatide dose in milligrams, our reconstitution calculator converts that into the exact syringe volume and insulin-syringe units it corresponds to — arithmetic on the number your prescriber gave you, not a suggestion of what that number should be.